YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov.…
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioThera…
Scopus BioPharma Inc. NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and it…
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-onc…
Scopus BioPharma Inc. Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately…
Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in…
Scopus BioPharma Inc. Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformatio…
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointme…
Scopus BioPharma Inc. Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology NEW YORK, March 22, 2022 (GLOBE NEWSWIRE) -- Scopus B…
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology NEW YORK, March 22, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq:…
Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual…
Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual…
Former CEO/Director Dr. Morris C. Laster Believes Election of New Directors to Scopus's Board Will Help Ensure Effective, Independent Oversight of Company's Affairs NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster…
Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPha…
Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPha…
Good morning, trader! We’ve reached the halfway point of the week and there’s no slowing down as we dive into the biggest pre-market stock movers for Wednesday! A view of the Federal Hall on Wall Street representing Pre-Market Stock Movers…
Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of Bi-Functional Cancer Targeting Molecules Recent…
Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of Bi-Functional Cancer Targeting Molecules Recent…
Former CEO/Director Dr. Morris C. Laster Believes Immediate Change is Required to Scopus's Board to Ensure Effective, Independent Oversight of Company's Affairs Deeply Concerned about the Company's Financial Underperformance and Plummeting…
NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announc…
NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announc…
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that, on November 5, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 11:30 a.m., Eastern time, on Mond…
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that, on November 5, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 11:30 a.m., Eastern time, on Mond…
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announc…
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announc…
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therape…
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therape…
Gainers CohBar, Inc. (NASDAQ: CWBR) rose 22.8% to $1.13 in pre-market trading after dropping over 4% on Friday. Farmmi, Inc.. (NASDAQ: FAMI) rose 13% to $0.3995 in pre-market trading after dipping over 23% on Friday. Farmmi recently issued…
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.…
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.…
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therape…
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therape…
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice Studies indicate Duet’s bifunctional ol…
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice Studies indicate Duet’s bifunctional ol…
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) Acceleron Pharma Inc. (NASDAQ: XLRN) Alker…
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-s…